Hillstream Biopharma (NASDAQ:CNTN) Stock Price Down 0.5% – Should You Sell?

Shares of Hillstream Biopharma Inc. (NASDAQ:CNTN) traded down 0.5% on Monday . The stock traded as low as $2.07 and last traded at $2.10. 481,455 shares changed hands during mid-day trading, a decline of 22% from the average session volume of 615,916 shares. The stock had previously closed at $2.11.

Analysts Set New Price Targets

Several research analysts have recently weighed in on CNTN shares. Wall Street Zen upgraded shares of Hillstream Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. Weiss Ratings downgraded shares of Hillstream Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 10th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Hillstream Biopharma Price Performance

The stock has a market capitalization of $160.56 million, a PE ratio of -4.05 and a beta of 1.47. The stock’s fifty day moving average price is $2.12.

About Hillstream Biopharma

Hillstream Biopharma, Inc is a clinical-stage biotechnology company focused on developing targeted therapies for cancer. The company’s research is centered on ferroptosis, a form of regulated cell death that can be used to target tumor cells, including cancers that may be resistant to conventional treatments.

Hillstream’s proprietary technology platform is designed to develop ferroptosis-activating compounds. Its lead investigational program, HSB-1216, has been developed as a potential treatment for advanced solid tumors.